US IPO By Peptor Of Israel
Israeli mdrug developer Peptor has filed with the US Securities andExchange Commission for an initial public offering of $2 million common shares, to be sold at $14-$16 each. The offering is expected to raise $30-$35 million.
The shares represent around 26% of the company's equity, according to underwriters Credit Suisse First Boston and Volpe Brown Whelan. There is also an overallotment option of up to 300,000 additional shares; after the offering the company will have 7.7 million common shares outstanding.
The stock will be traded on both the Nasdaq and the European board, the Easdaq. Peptor will be the first Israeli company to trade on the new European quotation exchange.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze